#United States #New York #Securities Fraud #Pomerantz Law Firm #Mereo BioPharma

Pomerantz Law Firm Files Class Action Lawsuit Against Mereo BioPharma Group

Pomerantz LLP, a renowned law firm specializing in class actions, has recently filed a class action lawsuit against Mereo BioPharma Group plc (NASDAQ: MREO). This follows a string of events that have significantly impacted the company’s stock price and raised concerns among investors regarding potential securities fraud and unlawful business practices.

Background on Mereo BioPharma

Mereo BioPharma is a UK-based biopharmaceutical company focusing on the development of innovative treatments for patients with rare diseases and cancer. The company’s stock has been under scrutiny following a series of announcements regarding its clinical trials that led to substantial declines in its share price. Invested parties are understandably alarmed as they seek ways to protect their investments.

Key Events Leading to the Class Action

The latest development that prompted this legal action occurred on July 9, 2025, when Mereo and its partner, Ultragenyx Pharmaceutical Inc., informed the public that the Phase 3 trial of UX143 (setrusumab) for treating osteogenesis imperfecta (OI) was not yielding favorable results. Following this announcement, Mereo’s stock price plummeted by over 42%, resulting in deep financial losses for investors.

Just months later, on December 29, 2025, Mereo disclosed that neither the Orbit nor Cosmic Phase 3 studies met the primary endpoint of statistical significance. Despite indications of improved bone mineral density, the news struck another serious blow to the company’s stock price, which fell a staggering 87.7% in one day, leaving the share price at just $0.29. This dramatic decline has galvanized investor concerns about the integrity of the company's communications and its leadership’s adherence to ethical business practices.

The Call for Investors to Act

As the lawsuit unfolds, Pomerantz LLP urges affected investors to act swiftly. Interested parties have until April 6, 2026, to request the court designate them as Lead Plaintiff in this class action. This designation would permit them to formally represent the interests of all investors who suffered losses as a result of Mereo’s actions. Investors can contact Danielle Peyton at [email protected] or reach out via phone at 646-581-9980 for further information and guidance on how to proceed.

About Pomerantz LLP

Pomerantz LLP is esteemed within the legal community, particularly for its expertise in corporate, securities, and antitrust class litigation. Founded over 85 years ago, it has established a reputation for asserting the rights of victims in securities fraud cases, achieving numerous multimillion-dollar awards for their clients. The firm continues to uphold the legacy of its founder by serving as a staunch advocate for investor rights and corporate accountability.

Conclusion

For those who have faced financial adversity due to Mereo BioPharma's actions, the opportunity to join this class action lawsuit could provide a pathway to recoup some of their losses. As the legal landscape develops, affected shareholders are encouraged to stay informed and consider their options in this pivotal timeframe.